Why I'd buy these ASX blue-chip shares until at least 2036

Résumé détaillé

I'm looking at three established businesses that could become more profitable over the next 10 years. The post Why I'd buy these ASX blue-chip shares until at least 2036 appeared…

Ten years is a long time to own an ASX share, so I think it's worth being selective about which businesses deserve that kind of commitment.

For me, three ASX blue-chip shares stand out because of the opportunities they have to become more profitable over the coming decade.

And while each has its own challenges, I'd be happy to buy their shares today with a view to holding until at least 2036.

Biotech leader CSL has spent decades building one of the world's leading plasma businesses, collecting donated plasma and turning it into medicines that treat serious immune and neurological conditions.

Demand for these treatments continues to grow, and I believe CSL is well-positioned to benefit.

Another thing I like is the company's ability to continue finding ways to produce more medicine from the plasma it collects.

Plasma collection and manufacturing are expensive, so even relatively small improvements in how much medicine CSL can produce from each litre could have a meaningful impact.

It could allow the company to treat more patients while reducing the cost of producing each treatment.

CSL is also investing in additional manufacturing capacity, including its US$1.5 billion expansion in Illinois, to support future demand.

Début de l'article, extrait de The Motley Fool Australia. Pour lire la suite, ouvrez l'article chez le média.